These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
221 related articles for article (PubMed ID: 10231452)
21. [Comparison of intravenous ascorbic acid versus intravenous iron for functional iron deficiency in hemodialysis patients]. Ogi M; Horiuchi T; Abe R; Wakabayashi M; Wakabayashi T Nihon Jinzo Gakkai Shi; 2004; 46(8):804-9. PubMed ID: 15645737 [TBL] [Abstract][Full Text] [Related]
22. [Correction of anemia in hemodialysis, effect of intravenous iron without erythropoietin]. Alvo M; Elgueta L; Aragón H; Cotera A Rev Med Chil; 2002 Aug; 130(8):865-8. PubMed ID: 12360794 [TBL] [Abstract][Full Text] [Related]
23. Erythropoietin therapy in pre-dialysis patients with chronic renal failure: lack of need for parenteral iron. Trivedi HS; Brooks BJ Am J Nephrol; 2003; 23(2):78-85. PubMed ID: 12481145 [TBL] [Abstract][Full Text] [Related]
24. Association between transferrin receptor-ferritin index and conventional measures of iron responsiveness in hemodialysis patients. Chen YC; Hung SC; Tarng DC Am J Kidney Dis; 2006 Jun; 47(6):1036-44. PubMed ID: 16731299 [TBL] [Abstract][Full Text] [Related]
25. The effect of i.v. iron alone or in combination with low-dose erythropoietin in the rapid correction of anemia of chronic renal failure in the predialysis period. Silverberg DS; Blum M; Agbaria Z; Deutsch V; Irony M; Schwartz D; Baruch R; Yachnin T; Steinbruch S; Iaina A Clin Nephrol; 2001 Mar; 55(3):212-9. PubMed ID: 11316241 [TBL] [Abstract][Full Text] [Related]
26. Epoetin requirement does not depend on dialysis dose when Kt/N > 1.33 in patients on regular dialysis treatment with cellulosic membranes and adequate iron stores. Movilli E; Cancarini GC; Vizzardi V; Camerini C; Brunori G; Cassamali S; Maiorca R J Nephrol; 2003; 16(4):546-51. PubMed ID: 14696757 [TBL] [Abstract][Full Text] [Related]
27. Intravenous iron dextran treatment in predialysis patients with chronic renal failure. Dahdah K; Patrie JT; Bolton WK Am J Kidney Dis; 2000 Oct; 36(4):775-82. PubMed ID: 11007680 [TBL] [Abstract][Full Text] [Related]
28. A Review of Ferric Pyrophosphate Citrate (Triferic) Use in Hemodialysis Patients. Albright T; Al-Makki A; Kalakeche R; Shepler B Clin Ther; 2016 Oct; 38(10):2318-2323. PubMed ID: 27692637 [TBL] [Abstract][Full Text] [Related]
29. Effect of intravenous ascorbic acid in hemodialysis patients with EPO-hyporesponsive anemia and hyperferritinemia. Attallah N; Osman-Malik Y; Frinak S; Besarab A Am J Kidney Dis; 2006 Apr; 47(4):644-54. PubMed ID: 16564942 [TBL] [Abstract][Full Text] [Related]
30. Slow intravenous iron administration does not aggravate oxidative stress and inflammatory biomarkers during hemodialysis: a comparative study between iron sucrose and iron dextran. Malindretos P; Sarafidis PA; Rudenco I; Raptis V; Makedou K; Makedou A; Grekas DM Am J Nephrol; 2007; 27(6):572-9. PubMed ID: 17804904 [TBL] [Abstract][Full Text] [Related]
31. [Treatment of iron deficiency by a bolus intravenous iron dextran in peritoneal dialysis]. Ficheux M; Cuny P; Lecouf A; Ryckelynck JP; Hurault de Ligny B; Lobbedez T Nephrol Ther; 2011 Dec; 7(7):558-61. PubMed ID: 21715234 [TBL] [Abstract][Full Text] [Related]
32. Ultrapure dialysate improves iron utilization and erythropoietin response in chronic hemodialysis patients - a prospective cross-over study. Hsu PY; Lin CL; Yu CC; Chien CC; Hsiau TG; Sun TH; Huang LM; Yang CW J Nephrol; 2004; 17(5):693-700. PubMed ID: 15593037 [TBL] [Abstract][Full Text] [Related]
33. The efficacy and safety of current intravenous iron preparations for the management of iron-deficiency anaemia: a review. Qunibi WY Arzneimittelforschung; 2010; 60(6a):399-412. PubMed ID: 20648931 [TBL] [Abstract][Full Text] [Related]
34. Long-term intravenous epoetin-alpha / darbepoetin-alpha ratio in iron-replete hemodialysis patients. Icardi A; Sacco P; Salvatore F; Romano U J Nephrol; 2007; 20(1):73-9. PubMed ID: 17347977 [TBL] [Abstract][Full Text] [Related]
35. Role of C-reactive protein, reticulocyte haemoglobin content and inflammatory markers in iron and erythropoietin administration in dialysis patients. El-Khatib M; Duncan HJ; Kant KS Nephrology (Carlton); 2006 Oct; 11(5):400-4. PubMed ID: 17014552 [TBL] [Abstract][Full Text] [Related]
36. Intravenous iron in chronic kidney disease: haemoglobin change shortly after treatment of patients neither on dialysis nor on erythropoietin. Tagboto S; Cropper L; Mostafa S; Turner J; Bailey G; Pugh-Clarke K J Ren Care; 2008 Sep; 34(3):112-5. PubMed ID: 18786076 [TBL] [Abstract][Full Text] [Related]
37. Comparative effects of erythropoietin with oral iron in peritoneal dialysis and hemodialysis patients. Raja R; Bloom E; Johnson R Adv Perit Dial; 1993; 9():177-80. PubMed ID: 8105918 [TBL] [Abstract][Full Text] [Related]
38. Hematologic and erythropoietin responses to iron dextran in the hemodialysis environment. Senger JM; Weiss RJ ANNA J; 1996 Jun; 23(3):319-23; discussion 324-5. PubMed ID: 8716991 [TBL] [Abstract][Full Text] [Related]
39. Intermittent versus maintenance iron therapy in children on hemodialysis: a randomized study. Ruiz-Jaramillo Mde L; Guízar-Mendoza JM; Gutiérrez-Navarro Mde J; Dubey-Ortega LA; Amador-Licona N Pediatr Nephrol; 2004 Jan; 19(1):77-81. PubMed ID: 14634860 [TBL] [Abstract][Full Text] [Related]
40. Treatment of iron deficiency anemia: are monomeric iron compounds suitable for parenteral administration? Gupta A; Crumbliss AL J Lab Clin Med; 2000 Nov; 136(5):371-8. PubMed ID: 11079464 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]